NovaBridge Biosciences (NBP) Receivables (2019 - 2023)

NovaBridge Biosciences (NBP) has 5 years of Receivables data on file, last reported at $2.7 million in Q4 2023.

• Quarterly Receivables fell 42.66% year-over-year to $2.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.7 million (down 42.66% YoY) and the FY2023 annual result came in at $2.7 million, up 77.53% from the prior year.
• Receivables fell to $2.7 million in Q4 2023 per NBP's latest filing, from $4.7 million in the prior quarter.
• Across five years, Receivables topped out at $57.8 million in Q2 2021 and bottomed at $2.7 million in Q4 2023.
• The 5-year median for Receivables is $6.4 million (2021), against an average of $22.8 million.
• The widest annual swing landed in 2020, when Receivables surged 1163.44%; it then sank 82.3% in 2021.
• Tracing NBP's Receivables over 5 years: stood at $2.9 million in 2019, then surged by 1163.44% to $36.1 million in 2020, then slumped by 82.3% to $6.4 million in 2021, then declined by 25.78% to $4.7 million in 2022, then sank by 42.66% to $2.7 million in 2023.
• Per Business Quant, the three latest NBP Receivables figures stand at $2.7 million (Q4 2023), $4.7 million (Q4 2022), and $49.1 million (Q2 2022).

Peer Comparison